EGT 101 - Egret Therapeutics
Alternative Names: EGT-101 - Egret TherapeuticsLatest Information Update: 27 Mar 2023
At a glance
- Originator Egret Therapeutics
- Class Anti-ischaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Ischaemia; Stroke
Most Recent Events
- 04 Feb 2023 US FDA approves IND application for EGT 101 in Ischaemia (Unspecified route)
- 03 Jan 2023 Egret Therapeutics plans a phase I/II trial for Ischaemia (Unspecified route) in 2023
- 03 Jan 2023 Preclinical trials in Ischaemia in USA (unspecified route) (Egret Therapeutics pipeline, January 2023)